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On the evolution of anti-aging medicine
The practice of anti-aging or age-management medicine (AAM) has undergone
logarithmic growth over the past decade and more. This fact is not necessarily
surprising. The desire for enjoying a full life span in a healthy, vital, and youthful
state is a universal human desire. Undoubtedly, this longing has caused people to
seek out practitioners who promote themselves as having the knowledge and methods
to at least approach the goal of healthy life extension through appropriate management
of senescence. However there are several characteristics of AAM that set it apart
from more traditional fields of medical practice. These include the following:
• AAM takes a health maintenance approach in therapy
• It was created by entrepreneurs not by those experienced in research on aging
mechanisms and interventions
• While an extensive research literature on aging exists, there is a paucity of data
and peer-reviewed papers on human responses to interventions in aging, and
• Until 2005, there was no legitimate and traditional forum for debate and exchange
of information by AAM practitioners.
Each of these characteristics are important and play a significant role in the current
status and future evolution of AAM. The AAM is on the cutting edge of clinical
medicine evolution because it is health-oriented. AAM is proactive rather than
reactive. Its intention is to avoid disease through health maintenance rather than
treat disease after it has become established. To achieve this goal, AAM takes a
holistic approach to therapy because its basic premise is that progressive loss of
homeostasis leads to functional decline and an increased risk for development of
intrinsic disease, ie, the commonly called “diseases of aging”. Because of this
philosophy, “replacement therapy” is currently the most basic clinical intervention
in aging. It has long been recognized that deterioration of homeostasis during aging
is associated with a progressive decline in essential informational, regulatory, and
protective molecules. Since adequate technology to slow or arrest underlying
homeostatic decline has not yet been developed, replacement of those naturally
occurring products including hormones, cofactors, anti-oxidants, etc. is routinely
employed. On the other hand, traditional medicine is disease oriented, ie, practitioners
prescribe medications to treat the symptoms of disease in patients presenting with
complaints about their health. Rather than taking a whole body, physiological approach
to therapy, AMM takes a segmented or body part, a pharmacological approach that is
based in large part upon the response of tissues or cells to xenobiotics that are
specifically designed and produced by pharmaceutical companies to relieve symptoms
of disease. The philosophical difference between this traditional approach and the
AAM approach is that the former presumes that symptomatic relief will restore whole
body well-being. However, except perhaps for antibiotics, traditional drug therapies
rarely if ever cure the underlying disease state. Thus, in the absence of therapies to
oppose age-decline in homeostasis and as senescence proceeds, more and more drugs
are used to suppress symptoms of increasing numbers of intrinsic diseases. This
leads to the conundrum in which a pharmacopoeia of drugs with significant risk for
malignant side effects and interactions are eventually needed to sustain life. Obviously,
a proactive, holistic approach intended to delay onset or avoid development of age-
related disease is more logical than a reactive, symptomatic approach. Eventually,Clinical Interventions in Aging 2006:1(3) 202
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traditional medicine must embrace this philosophical change
if it is to provide effective patient care in the future.
The problem with AAM serving as a model for medical
philosophical evolution is that it was created by
entrepreneurial businessmen responding to market
opportunities rather than by those who are experienced in
research and clinical management of aging issues.
Furthermore, their efforts and successes were based almost
exclusively upon the merits of a single study that was
published in the New England Journal of Medicine in 1990
(Rudman et al 1990). The now famous paper authored by
the late Daniel Rudman and colleagues showed that certain
“youthful” qualities of form and function could be simulated
in elderly men by administration of human growth hormone
(hGH). These findings were sensationalized by the press in
a number of exaggerated reports published in popular
magazines and articles. For example, in October 1992, LIFE
Magazine ran a cover page story entitled “Can we stop
aging” in conjunction with a composite picture of a woman
named Sally Woodbridge as she appeared in 1944 and 1992.
The lead article of this issue was entitled, “The war on
aging”, which included a dramatically symbolic photograph
of one of Rudman’s elderly subjects, smiling youthfully
while standing in a virgin forest with sunbeams falling on
his muscled arms (Darrach 1998). Understanding the
marketing significance of this display and the public demand
for product upon which it was based, entrepreneurs
immediately took the lead in commercializing hGH and
founding an anti-aging movement. As if in a gold rush, sales
of anti-aging nostrums and access to the “fountain of youth”
rapidly became associated with AAM, tainting it in the minds
of legitimate practitioners, who under other circumstances
might have helped advance the field. Immediately following
publication of Rudman’s paper, other respected researchers
stated that the age-related decline in GH and other hormones
could contribute to senescence in varying degrees and
conversely that hormone replacement might have some
benefit in preventing such maladaptive change (Corpas
1993). Sadly, these endorsements were subsequently
withdrawn in light of the commercialization of AAM, despite
the fact that at the time a National Institute on Aging existed
for over two decades and a significant literature on aging
and life extending interventions existed, albeit mostly in
animal models. Compounding the problem was the fact that
in contrast to their peers practicing traditional medicine, the
growing number of AAM practitioners failed to collect
outcomes data and to report their findings in medical
journals. At the time, AAM organizations only published
magazines whose purpose seemed to be advertising rather
than medical information exchange, so legitimate growth
of the fledgling specialty was further hampered. This
absence of a peer-reviewed, legitimate record of outcomes
from AAM interventions in aging led to an outcry that an
ongoing “experiment” was being conducted in human
subjects without protection or benefit of competent
oversight.
In response to these potentially destructive issues and
recognizing that for the most part AAM practitioners are
seeking evidence based approaches to age management, a
nucleus of activists have been working over the past two
years to create an alternative perspective on the field. The
specific objectives of their efforts are to promote education,
stimulate debate and information exchange, and contribute
positively to the evolution of AAM as a legitimate medical
specialty. As previously discussed (Walker 2006) central to
this effort is a professional society that will function as any
other non-profit group with a duly elected and rotating
president, officers and board of directors. It will hold regular
membership meetings and be devoted to education, support
of research and service to its constituents. That group is the
international Society for Applied Research in Aging (SARA;
www.agesociety.org) which will be holding its second
annual meeting on November 10–12, 2006 in Las Vegas,
Nevada, USA. The meeting will be held in cooperation with
the Age Management Medicine Group (AMMG;
www.agemed.org), a respected professional organization
whose goal is to provide education and information on the
new sub-specialty of AMM to physicians and healthcare
professionals through evidence-based continuing medical
education conferences, workshops, seminars, publications
and web media. So as to provide an interactive opportunity
for AAM practitioners, the official SARA journal, Clinical
Interventions in Aging will expand its format to include a
section in which brief communications and comments on
clinical issues can be submitted for editorial response as
well as reply by the readership. Unlike the main body of the
Journal, this interactive venue will not be subject to peer
review because those sending submissions will get feedback
in print directly from colleagues in support of or against
their views. Hopefully, this opportunity will engender lively
discussion on current topics between practitioners and also
provide both within the peer-reviewed sections and without,
a historical perspective on the evolution of legitimate,
evidence-based interventions in aging. Through such
cooperative efforts of caring professionals, anti-aging
medicine, age-management medicine or whatever name oneClinical Interventions in Aging 2006:1(3) 203
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chooses to use for describing therapies intended to sustain
health, vitality, and good quality of life during aging will
eventually take its lead place in guiding the evolution of
medical philosophy and practice.
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